Skeletal Targeted Radiotherapy: Phase I/II data; Phase II

In NERX’s Phase I/II trial, 18 of 40 evaluable patients had complete remissions (absence of the M-protein myeloma marker), without increased serious toxicity. Patients were treated with high-dose or c...